Headache News and Research

Latest Headache News and Research

People without migraines can filter out more visual noise: Study

When people feel the onset of a migraine headache, they may head to a dark, quiet room to rest. This instinct may be sound: A new study suggests that even without the headache, migraine sufferers may process visual cues better in an environment with few visual distractions.

12 Apr 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

The antiepileptic drug Vimpat- (lacosamide) (C-V) will be the subject of numerous studies and analyses-both UCB-sponsored and independent-at the 62nd annual American Academy of Neurology meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17.

9 Apr 2010

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.

8 Apr 2010

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

MAP Pharmaceuticals, Inc. today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX™ orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography.

8 Apr 2010

MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

MAP Pharmaceuticals, Inc. today announced the Company will present additional post-hoc analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy in two patient subpopulations that are often difficult to treat with current triptan migraine therapies: menstrual migraine and migraine with allodynia.

7 Apr 2010

Are Australians popping too many pills?

These reports have emerged from a Daily Telegraph investigation. Australian Medical Association vice president, GP and former Pharmaceutical Benefits Advisory Committee member Dr Steve Hambleton said the resons for these trends may include the increasing population of the aged, newer medicines as well as a rise in chronic lifestyle ailments like diabetes and high blood pressure.

5 Apr 2010

2010 Internal Medicine conference at Toronto Convention Center

More than 5,000 internists (adult medicine specialists), subspecialists, medical students, and allied health professionals will meet in Toronto, Canada, for Internal Medicine 2010, the annual scientific meeting of the American College of Physicians (ACP), April 22 - 24 (Thursday - Saturday), at the Toronto Convention Center.

2 Apr 2010

Gastrointestinal tract disorders GERD and IBS interlinked

Gastroesophageal reflux disorder (GERD) and irritable bowel syndrome (IBS) are two very common disorders affecting the gastrointestinal tract. About 10% of the population experience daily discomfort from reflux of gastric contents into the esophagus. More than 10% of the population experience abdominal pain and disturbed bowel movement because of irritable bowel syndrome.

2 Apr 2010

Schering-Plough HealthCare Products commences promotion of ZEGERID OTC in North America

Santarus, Inc., a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc., the consumer healthcare subsidiary of Merck & Co., Inc., has commenced promotion of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its licensing agreement with Santarus for the over-the-counter (OTC) market in North America. The OTC heartburn market in the U.S. is estimated at approximately $1.8 billion based on data from market research firm Information Resources, Inc. and Santarus estimates.

2 Apr 2010

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.

31 Mar 2010

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

Pfizer Canada is pleased to announce the recipients of its third Neuropathic Pain Research Awards Competition, which aims to fund and support Canadian innovation within independent neuropathic pain research in the areas of basic biomedical, clinical and health sciences.

31 Mar 2010

Top neurologists to receive 2010 AAN Alliance Awards

The American Academy of Neurology will recognize the outstanding achievements of researchers in neurology during the AAN's 62nd Annual Meeting in Toronto, April 10 through 17, 2010, the world's largest gathering of neurologists with more than 2,000 presentations on the latest advances in neurologic research.

31 Mar 2010

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

Cephalon receives FDA Complete Response Letter for NUVIGIL supplemental new drug application

Cephalon, Inc. today announced the company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for its supplemental new drug application for NUVIGIL® (armodafinil) Tablets [C-IV] in the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.

30 Mar 2010

Norovirus outbreak associated with oysters: FDA and Mississippi, Louisiana public health agencies issue warning

The U.S. Food and Drug Administration is working with state health officials from Mississippi and Louisiana to notify consumers, food service operators and retailers nationwide about an outbreak of norovirus associated with oysters recently harvested from an area near Port Sulphur, La. known as Area 7. The oysters were sold or distributed nationwide.

27 Mar 2010

FDA: Outbreak of campylobacteriosis linked to drinking raw milk

The U.S. Food and Drug Administration, along with several state agencies, is alerting consumers to an outbreak of campylobacteriosis associated with drinking raw milk. At least 12 confirmed illnesses have been recently reported in Michigan. Symptoms of campylobacteriosis include diarrhea, abdominal pain and fever.

27 Mar 2010

Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy

Medtronic, Inc. today announced the enrollment of the first European patients in the largest randomized controlled trial to date to investigate the benefits of ITB Therapy(R) (Intrathecal Baclofen) in post-stroke patients affected by spasticity. The announcement comes as the World Congress for Neurorehabilitation is taking place in Vienna, Austria.

26 Mar 2010

Researchers identify link between socioeconomic status and common disease symptoms

Researchers have identified the link between socioeconomic status and common symptoms of disease, prompting new questions about the causal connections between them.

26 Mar 2010

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

Shire plc, the global specialty biopharmaceutical company, today presented positive data from a Phase III clinical trial (TKT-034) designed to evaluate the safety of switching to VPRIV (velaglucerase alfa for injection), from imiglucerase, as well as an interim analysis of safety data from an ongoing multicenter open-label treatment protocol (HGT-GCB-058) implemented to provide VPRIV to patients affected by the continuing shortage of imiglucerase.

26 Mar 2010

Mexican-American women les likely to use emergency medical services for stroke symptoms

Mexican Americans are 40 percent less likely than non-Hispanic whites to call 9-1-1 and be taken to the hospital via ambulance for stroke - resulting in medical treatment delays - according to a new study reported in Stroke: Journal of the American Heart Association.

26 Mar 2010

Headache News and Research

Latest Headache News and Research

People without migraines can filter out more visual noise: Study

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

Are Australians popping too many pills?

2010 Internal Medicine conference at Toronto Convention Center

Gastrointestinal tract disorders GERD and IBS interlinked

Schering-Plough HealthCare Products commences promotion of ZEGERID OTC in North America

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

Top neurologists to receive 2010 AAN Alliance Awards

Patients switching to Victoza experience further reductions in A1c and weight loss

Cephalon receives FDA Complete Response Letter for NUVIGIL supplemental new drug application

Norovirus outbreak associated with oysters: FDA and Mississippi, Louisiana public health agencies issue warning

FDA: Outbreak of campylobacteriosis linked to drinking raw milk

Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy

Researchers identify link between socioeconomic status and common disease symptoms

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

Mexican-American women les likely to use emergency medical services for stroke symptoms

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in